Lexeo Therapeutics Reports Q2 2026 Financial Results with $25.9M Net Loss

Lexeo Therapeutics, Inc. reported its financial results for the second quarter of 2026, revealing a net loss of $25.9 million, a slight improvement from a net loss of $26.1 million in the same period last year. For the six months ending June 30, 2026, the company recorded a net loss of $46.1 million, compared to $58.8 million for the first half of 2025. The company’s total operating expenses decreased to $28 million for the quarter, down from $30.7 million in the prior year, primarily due to a reduction in general and administrative expenses, which fell from $16 million to $9 million. Research and development expenses increased to $19 million, reflecting ongoing clinical trial costs.

Lexeo's cash and cash equivalents, along with investments in U.S. Treasury securities, totaled $234.2 million as of June 30, 2026, a decrease from $246.6 million at the end of 2025. The company raised approximately $25 million through its at-the-market (ATM) program during the quarter, selling 4.4 million shares at an average price of $5.65 per share. In July 2026, Lexeo further raised about $14.1 million by selling an additional 3.1 million shares under the same program. The company anticipates that its current cash reserves will be sufficient to fund operations into 2028.

Operationally, Lexeo is advancing its lead product candidates, LX2006 and LX2020, which are in clinical trials for treating Friedreich ataxia cardiomyopathy and arrhythmogenic cardiomyopathy, respectively. The company has reported positive interim clinical data for both candidates, with LX2006 receiving Breakthrough Therapy designation from the FDA in July 2025. The SUNRISE-FA 2 pivotal study for LX2006 was initiated in June 2026, with plans for a Biologics License Application (BLA) submission expected in the first half of 2028.

The company’s employee headcount has increased as it continues to build its operational capabilities, particularly in research and development. Lexeo is focused on expanding its clinical pipeline and enhancing its manufacturing capabilities, which may require additional funding. The company has indicated that it will need to secure further capital to support its ongoing and future development programs, as it has not yet generated revenue from product sales. The outlook remains cautious, with expectations of continued operating losses as the company advances its clinical trials and seeks regulatory approvals.